Background: In order to develop a more effective prophylactic HIV-1 vaccine it is important optimize the components, improve Envelope glycoprotein immunogenicity as well as to explore prime-boost immunization schedules. It is also valuable to include several HIV-1 subtype antigens representing the worldwide epidemic. Methods: HIVIS-DNA plasmids which include Env genes of subtypes A, B and C together with Gag subtypes A and B and RTmut/Rev of subtype B were modified . HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vacciniabased boosts induce both humoral and cellular murine immune responses to HIV.
Introduction
The best and most impressive preventive measure against infectious diseases has been vaccination. Over twenty different infectious diseases are preventable today by immunization. However, several serious viral infections, such as human immunodeficiency viruses, most of the herpes viruses and the hepatitis C virus lack efficient vaccines. One common property of these viruses is that they rapidly become chronic or persistent before protective immunity is established. Attempts to develop prophylactic or therapeutic vaccines or a cure against HIV have been going on for more than three decades, with lessons learned from several trials [1, 2, 3, 4, 5] . The Immune space presents variables such as immunoprofiles that can be used to assess and select future vaccine components [6] .
Genetic/DNA vaccines have shown promise for priming of immune responses, both for antibody production and for cell-mediated immunity. In non-human models the induction of protective immunity to infectious diseases and tumors has been impressive [7] [8] [9] [10] . In humans and larger animals, difficulties were encountered with delivery systems and with expression of correct conformational proteins/peptides. A few protective or therapeutic schedules obtained by genetic vaccination were revealed [8, 11, 12, 13] .
To obtain broad antibody and cell mediated immunities, the concept of prime-boost has proven effective. Heterologous vaccine strategies incorporating DNA, MVA and or HIV protein have been shown to augment and improve the quality of the immune response in mice [14] [15] . Both these approaches have met with modest success, and at best one of the prophylactic HIV-1 vaccine trials has obtained 60% early and 31,2% endpoint protective effects [16, 17] . These findings emphasize the importance to induce high quality long-term memory, recently acquired by a prime-boost schedule containing heterogeneous HIV-1 components [18, 19, 20] [21].
An HIV-1 vaccine for prophylactic use should be capable of eliciting potent antibody-mediated protection but also cell-mediated immunity against several HIV-1 subtypes, while a therapeutic vaccine is expected to work mainly by cellmediated immunity and antibody dependent cellular immunities (ADCC) [22, 23] .
HIVIS-DNA represents HIV-1 subtypes A, B and C [21, 24, 25] . The HIVIS-DNA has been the priming part followed by a vaccinia-based boost (MVA-CMDR) in several clinical trials that have induced broad and strong and long-lasting humoral and cellular immune reponses [19] [20] [26] . The priming schedule is however complex since several plasmids are combined. We have reduced the complexity in clinical trials by showing that intradermal needle-free delivery gives better immune responses than intramuscular [27] , that higher doses in smaller volumes can improve responses [28] and that, in difference to animal studies, a combination of all plasmids results in as good responses as the separation of Gag from Env plasmids [29] . In order to reduce the complexity of the HIVISDNA and retain the reduced DNA amount to be given intradermally and still represent the various HIV antigens in separate plasmids, we optimized Env plasmids further by codon optimization, reduction in length and introduced an FT4 trimerization unit, thus eliminating the Rev plasmid that is not highly immunogenic. The RT plasmid was shortened to include the most prevalent epitopes and expressed together with an enzymatically destroyed PR which harbors several potent epitopes for cell mediated immunity. We thus obtained HIVISopt-DNA which was compared in an experimental system to reveal better immune responses or non-inferiority to HIVIS-DNA, finally for clinical purposes.
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The murine model may be used to assess applicability of several variables that would benefit a human vaccine schedule. Generally we could establish a noninferiority of the new HIV-DNA priming composition, and since these comparisons were done in parallel we might assume that the optimized HIVISopt-DNA can act to induce broad humoral and cellular immune responses in humans, similar to or better than the HIVIS-DNA, followed by the MVA-
CMDR.
Finally, trials in humans need further preparation, such as selection and composition of plasmids in relation to one another, dosing of primes and boosts, and decisions on rapid or protracted immunization schedules to obtain long-term memory. The present aim was to refine immunization components and schedules using a preclinical model. Table 1 :
Materials and methods

Immunogens
Gag p37 A and B, Env gp160 A, B, C, reverse transcriptase (RT) and Rev B [21] [24] [30] [31] . HIVISopt-DNA plasmids consist of gp150 subtypes A, B and C modified to contain FT4C-terminal ends to improve trimerization by T4 fibritin [32] together with p37 Gag A and B plus PRidelRT (aa mut, 413 aa) [33] . In summary, the original immunogen composition of HIVIS-DNA contains a Revexpressing plasmid, which was exchanged for shortening of the Env plasmids at Article No~e00339 the C-terminal site, providing them with FT4 endings and a change of several nucleotide triplets to improve expression. The immunodominant gp41 region was mutated in all constructs. The RT plasmid was shortened to include the most prevalent epitopes inducing cell mediated immunity (Los Alamos) and expressed together with an enzymatically destroyed PR which harbors several potent epitopes for cell mediated immunity. Gag plasmids were not revised. Fig. 1 shows a schematic picture of vaccine compounds. 
Animals and immunizations
Female BALB/c mice (6-8 weeks old, H-2D d ) were housed at the Astrid Fagraeus animal facility at Karolinska Institutet. HIV-1 DNA-plasmids were dissolved in saline and given intradermally (ID) at two separate injection sites on the shaved flanks of the mice. Plasmids encoding Gag and RT were mixed and given intradermally on the shaved right flank (100 μl volumes, 200 μg, at a DNA concentration of 2 mg/ml). Plasmids encoding Env subtypes A, B and C with (HIVIS-DNA) or without (HIVISopt-DNA) Rev subtype B were mixed and given intradermally on the shaved left flank. Both immunizations were given by Biojector®, immediately followed by electroporation (EP) [15, 38, 39, 40, 41, 42] .
EP was performed over the immunization site (DermaVax, Cellectis, Romainville, France; pulse frequency and amplitudes according to Roos et al. [38] ). MVA-CMDR was given intramuscularly (IM) twice. Mice immunized with recombinant vaccinia vector were given 10 7 plaque forming units (PFU) of MVA-CDMR intramuscularly in the hind legs in 50 μl of phosphate buffered saline (PBS) [34] .
Sera were sampled before and at 10-20 days after boost immunizations. Spleens were sampled at the end of each study ( Table 1 ). In these, as well as in previous experimental studies, general health and significant and similar growth curves of individual mice participating in the prime-boost studies were noted. Ethical permission was obtained from the Northern Stockholm Board of Animal Ethics dnr N66/13. 4 Median <20 <20 <20 <20 <20 <20 <20 <20 <20
Range <20 <20 <20 <20 <20 <20 <20 <20 <20
Response 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5
HIV-1 isolates were used at 25-30 TCID50 concentration. 50% and 80% neutralization titers are show, as well as titer ranges between individuals. No. of responding individuals are shown for 50% neutralization of each strain.
Group 1B received Env components of subtype A (DNA and MVA), B (DNA), C (DNA), E (MVA).
Group 2B received Env components of subtype A (DNA and MVA), B (DNA), C (DNA), E (MVA).
Group 3B received Env components of subtype E (MVA).
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(aa 652-661), B (aa 661-676) and C (aa 551-566). The CCR5 peptide represents the cellular HIV-1 co-receptor (Los Alamos database, http://www.hiv.lanl.gov/and Thermohybaid, DE). Microplates (Nunc Maxisorb, DK) were coated with 100 μl/ well of each antigen and sera assayed as described [33, 43] . For peptide ELISAs, absorbance values are given for serum dilutions of 1:20. (Table 3 and Tables 4 and 5 ). 
Neutralization assay
Results
Binding antibodies
An overview of antigens used is given in Fig. 1 . Groups of Balb/c mice were primed once by HIV-1HIVIS-DNA (Groups 1 A and B) or HIVISopt-DNA (Groups 2 A and B), followed by one or two MVA-CMDR boosts, or given only MVA-CMDR once or twice (Groups 3 A and B) ( Table 1) .
Anti-Env gp140C and anti-Env gp160 B (not shown) binding antibodies were primed by both HIVIS-DNA and HIVISopt-DNA and were considerably boosted by the second MVA-CMDR boost ( Fig. 2A , p < 0.01, p < 0.05 and p < 0.05). The group primed by HIVISopt-DNA following the first MVA-CMDR boost obtained slightly higher (ns) median titers than the group primed by the native HIVIS-DNA. Following the second MVA-CMDR boost, both DNA primed groups obtained high and similar titers (p = 0.29, median titers 10 000-50 000). Without DNA priming, the MVA-CMDR second immunization resulted in significant boosting of anti-Env primed group. It is notable that the group primed with HIVISopt-DNA (both primes contain a plasmid expressing Env C) primed group gave higher reactivity to Env gp140C antigen than the non-primed group after two MVA-CMDR immunizations (MVA-CMDR does not contain Env C) ( Fig. 2A , p < 0.05).
Antibody measurements to Gag p55 B (Fig. 2B) shows that HIVIS-DNA and
HIVISopt-DNA induce similar levels of antibodies after the first boost with MVA-CMDR. After the second boost with MVA-CMDR, the HIVIS-DNA had primed antibody titers to Gag to higher levels than HIVISopt-DNA (p < 0.05). There is no difference in Gag plasmid composition between HIVIS and HIVISopt immunizations ( Table 1 ). The highest median binding endpoint titer against Gag was obtained in the HIVIS-DNA primed group, around 15 000. A substantial reduction in antibody titers to Gag was observed after the second injection of MVA-CMDR.
Sera from five animals were pooled within groups in an attempt to identify antipeptide serological immune responses. The gp120 V3 peptide was recognized by all groups (Fig. 3A-C) . The Gp41 peptides were selected from sites of HIV-1 subtypes A, B and C strains assumed to induce broad neutralization (see Methods).
Here, the gp41 subtype B peptides were clearly recognized by all immunized groups, while the subtype A gp41 peptide was weakly recognized only by HIV-DNA primed animals. Control peptides representing the human HIV co-receptor CCR5 of cellular origin and not present in the vaccines were used to estimate background antibody levels. Pre-immune sera had very low responses to any peptide (Fig. 3D ).
Neutralizing antibodies
Neutralizing titers were assayed against viruses of HIV-1 subtypes A, B, C and CRF01_AE strains ( Table 2 ). Neutralization titers were assessed after HIVIS-DNA or HIVISopt-DNA priming and twice boosted by MVA-CMDR. There was no major difference between the neutralization titers between HIVIS-DNA and HIVISopt-DNA primed mice after 2 MVA-CMDR boosts. Two immunizations with MVA-CMDR also resulted in neutralizing titers to all strains, with generally lower median titers. The HIV-1CRF01_AE strain was neutralized by all groups at titers of 60-160.
DNA priming generally increased median neutralizing titers to subtypes B and C.
Prime-boosted groups had the highest median neutralization titers of around 700-760 against the consensus HIV-1 III B strain. Sera from non-immunized controls (and pre-immunization sera, not shown) were all negative ( Table 2 ). (group 2 B see Table 1 ). All five animal sera neutralized HIV-1 subtype C, with a median neutralization titer of 220.
Cell mediated immune responses
After one HIV-DNA priming followed by a first and second MVA-CMDR boost we noted cell mediated responses to peptides derived from Env (subtype E), Gag (subtype A) and Pol (subtype A) ( Fig. 5A and B) . Gag reactivity after HIVIS-DNA or HIVISopt-DNA priming was boosted by one MVA-CMDR immunization (Fig. 5B) . Two MVA-CMDR boosts raised IFNγ spots significantly for the HIVIS-DNA primed group (p < 0.01). The cell mediated responses were lower when the group that received MVA-CMDR only, had not been primed (p < 0.01).
[ ( F i g . _ 4 ) T D $ F I G ] Pol peptides of the CMDR subtype A origin were used for a similar experiment, Fig. 5C . Here all three animal groups showed 400-800 SFC/million spleen cells after one MVA-CMDR boost. Two MVA-CMDR immunizations did not increase the anti-Pol cellular immunity (Fig. 5C ), similar to findings with the Env or Gag peptide antigens ( Fig. 5A and B) . It is likely that addition of PR sequences to HIVISopt-DNA (Table 3) contributed to the higher (p < 0.05) cellular reactivity following HIVISopt-DNA priming and MVA boosting.
The Con A activation of spleen cells from immunized mice showed a median of around 8 000-10 000 SFC/10 6 cells, the medium control 40-70 SFC/10 6 cells (not shown). Control non-immunized mice had a median of around 2 000 SFC/10 6 cells after Con A activation, and 30 SFC/10 6 cells with Env, Gag and Pol peptides.
[ ( F i g . _ 5 ) T D $ F I G ] Peptide pools representing segments of the HIV-1 subtype B Pol region were used in an attempt to map cellular responses ( Table 3 ). The addition of PRidelRT plasmid to HIVISopt-DNA gave rise to cell mediated responses to both RT and PR peptides. In total, these responses were similar after priming with HIVIS-DNA or HIVISopt-DNA, however the variation of reactivity to these peptide pools was considerable. The highest median spot level was obtained for PR peptides after
HIVISopt-DNA priming and one MVA-CMDR boost (196, range 61-1744 spots).
Thus, for cell mediated immunity, MVA-CMDR appears to be a strong boosting agent for both types of HIV-DNA priming whether HIVIS-DNA or HIVISopt-DNA ( Fig. 5A and B 
Discussion
Recent clinical HIV-1 vaccine trials or studies in primates have used prime-boost schedules, often with combinations of DNA plasmids with viral vectors such as Pox-or Adenovirus-based vectors [1, 20, 44, 45, 46, 47, 48] . It is also anticipated that the novel idea of using a latency-forming vector, based on replicating Cytomegalovirus, may be helped by HLA-E/KIR in inducing novel CD8+ cellular responses [49, 50] .
Broadly neutralizing humoral antibodies have been described following multiclade HIV-DNA plasmids [51, 52] and recombinant protein booster immunizations in primates [47] , rabbits [53] , and rodents [21, 52, 54, 55] . In clinical studies with HIV-DNA prime, the virus-reducing activities of antibodies have been characterized as neutralization [56] or prominent ADCC reactivity [23] , for a review see [22] . [57]. Likewise, cell mediated immune responses of long duration have been induced to several subtypes as represented by peptides overlapping the HIV-1 Env and Gag sequences [19, 20] . The studies have demonstrated dose sparing and simplification of DNA administration and priming in human trials [27, 28] .
For larger clinical studies it is important to reduce the number of vaccine components while still not compromising the excellent broad cell mediated immunities and functional antibody responses of long duration. For this purpose we modified the HIV-DNA, MVA-based immunization schedule. Our rational was to retain representation of long Env and Gag proteins from multiple HIV subtypes, while reducing the number of plasmids and still add immunogenic epitopes. An overview of the subtype-specific antigens represented in the prime and boost immunizations is given in Table 1 .
The relative immunological responses to two prime-boost schedules were evaluated in a murine model. [19] . We ascribe these results to the heterogenous composition of the vaccine, including full sequences from strains of subtypes A, B and C in the prime and E (AE) in the boost.
This was a first attempt to compare neutralizations between the two immunization schedules. We have therefore started to assay against strains of several subtypes with which we are familiar and also represent the subtypes included in the vaccine The HIVISopt-DNA primed a larger number of epitope responses to Pol, also anticipated since the antigen PR was added and RT modified in these plasmids.
Expression of RT has [57] been shown to be significantly higher in the PRidRT construct of HIVISopt than that of RT from the RTmut construct of HIVIS-DNA [33] . In that study, PR related cell mediated immune responses occurred of around 2 000 SFC/10 6 cells, a reactivity that was similar or higher when PRidRT was combined with HIVIS-DNA plasmids [33] .
The reasons for the MVA-CMDR not continuing to boost cell mediated immunity when given the second time as seen in the present study, cannot be easily explained. Similar phenomena occur with relative antigen overload or when timing between two strong antigens is too short. Two immunizations with MVA-CMDR as given here may require a longer time interval than 3 weeks between these potent boost immunizations to obtain the best contraction of primarily induced B-and Tcell immune responses. The MVA-CMDR humoral Env responses were boosted by the second HIV-MVA immunization, but Gag antibody and Gag cellular responses were not boosted. It is known that kinetics for humoral and cell mediated responses as well as for different antigens differ, and we may not have been able to access the optimal time point for both [59] . Here, this was evident for antibody induction to Gag and cell mediated reactivities to Gag and Pol. This work, as well as other studies, highlight that DNA vaccines potently prime potent immunogenicity in mice although this may not translate in nonhuman primates and human studies. In fact, the DNA prime and MVA boost model has shown variable levels of immunogenicity in humans [60] [20] [19] [1] .The reasons for the variability between studies are multiple. Except for the species selected, the age and sex play roles [19] . The expression of plasmids and vectors may vary related to tissue in which they are delivered, facts that might be modulated with new formulations of DNA to better enhance immunogenicity.
Correct delivery and dosing of DNA are key questions for good expression of plasmid DNA. Both needle-less Biojector® and electroporation have been proven efficient means to increase numbers of transfected cells expressing antigens [2, 40, 41, 61, 62] . Delivery of DNA to mice appears to be optimal by Biojector® or electroporation targeted in the skin, which is resident to large numbers of dendritic cells [15] . In humans, the needle-less Biojector® works well after delivery of DNA plasmids to the skin, comparable to vaccine delivery by electroporation [2] .
It is well known that mice respond well to DNA vaccines in contrast to many larger animals. The limitations of the presented results generated in Balb/c mice do not take into account dosing or delivery systems for humans, which we have shown to be important for the HIVIS-DNA priming in clinical trials.However, we feel that the small animal system can be used for comparisons between vaccine schedules related to certain criteria such as general trends for indicating whether B-cell or Tcell responses would be improved or similar.
We intended to show non-inferiority of the reduction and compression of antigens in the HIVIS-DNA vaccination schedule, which would be useful for clinical trials.
This was successful and allows continuation with either the 6 or 7 component DNA vaccine.
Late boosts are essential to retain good immunological memory. Extended identification of remaining B-and T-cell memories have been revealed after DNA prime, MVA boosts in the clinic [20] [26] . The clinical study RV144 experienced a higher rate for protection early, which waned until the pre-decided endpoint [17] . It was notable in the present study, that priming once with DNA followed by one MVA boost induced higher immune responses than one MVA alone and at times even two MVA boosts. In a coming clinical trial it might therefore be optimal to start immunizations by one high dose composite DNA prime and one high dose MVA boost, followed at 2-3 yearly intervals with the same schedule. This would provide good initial priming and very long-term memory responses.
